Menopause-related symptoms affect quality of life for hundreds of millions of women worldwide. Hormone replacement approaches remain central to care, yet formulation differences can materially change how therapies perform in real patients—bioavailability, consistency, and tolerability all matter as much as the active molecule on the label.
JASTLabs is advancing a proprietary hormone replacement therapy platform designed around those practical realities: improving delivery characteristics that influence day-to-day symptom relief and long-term adherence. Our early-stage work focuses on formulation robustness and measurable pharmacokinetic endpoints that align with what regulators and clinicians expect to see as programs mature.
This progress does not stand alone. It sits alongside our broader mission to bring disciplined pharmaceutical development to women’s health—pairing bench insight with a development strategy aimed at FDA-aligned evidence generation. As we continue preclinical and formulation studies, we will share milestones consistent with our obligations to investors and the public markets.
For accredited investors and stakeholders following our journey, the takeaway is straightforward: we are building a platform intended to compete on science and execution—not slogans—with women’s lived experience at the center of every technical decision we make.